C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - Slideshow (opens in new tab)

2026-06-20. The following slide deck was published by C4 Therapeutics, Inc.